Meta analysis of efficacy and safety of LCZ696 in treatment of heart failure
He Yuqin1, Liu Yongming2, Yan Fangfang1
2020, 35(7):
581-588.
doi:10.3969/j.issn.1004-583X.2020.07.001
Asbtract
(
553 )
PDF (1587KB)
(
408
)
HTML
Related Articles |
Metrics
Objective To evaluate the efficacy and safety of LCZ696 in the treatment of heart failure by searching its RCTs at home and abroad.Methods The Cochrane library, Pubmed, Web of science, CNKI, VIP, Wanfang database were searched for literatures on LCZ696 for heart failure. And the literature were screened according to the inclusion and exclusion criteria.The bias risk assessment tool in Cochrane intervention system evaluation manual version 5.1.0 was used to evaluate the quality of included studies, and RevMan 5.3 software was used to conduct the metaanalysis of all outcome indexes.Results A total of 14 967 patients were enrolled in 6 RCTs studies. Combined outcome indicators showed that LCZ696, LAVI ( WMD=-2.18, 95%CI[-3.63, -0.74], P=0.003), E/e' (WMD=-1.01, 95%CI[-1.89, -0.12], P=0.03), mortality (RR=0.89, 95%CI[0.83, 0.96], P=0.003), the rate of rehospitalization for heart failure (RR=0.83, 95%CI[0.78, 0.88], P<0.01) decreased more significantly after the treatment, while the quality of life score (WMD=1.32, 95%CI[0.69, 1.95], P<0.01) and the incidence of symptomatic hypotension (RR=1.46, 95%CI[1.34, 1.60], P<0.01) increased more significantly.ConclusionLCZ696 can significantly reduce the mortality and rehospitalization rate of patients with heart failure, and it does not increase the risk of adverse events such as renal injury, angioedema and hyperkalemia.